演題抄録

一般演題 (示説)

開催概要
開催回
第53回・2015年・京都
 

The potential impact of pegfilgrastim on adjuvant chemotherapy regimens and dosage, a single institution experience

演題番号 : P52-7

[筆頭演者]
Kamada Yoshihiko:1 
[共同演者]
Tamatsu Youko:1、Arakaki Miwa:1、Yamashiro Kazuko:1、Tamaki Kentaro:1,2、Uehara Kano:1,2、Tamaki Nobumitsu:1,2

1:Department of Surgery, Nahanisi Clinic、2:Nahanishi Clinic Makabi

 

Background: Pegfilgrastim has recently been approved for prevention of neutropenia in high dose tri-weekly chemotherapy regimens. We have been using pegfilgrastim since December 2014, and all patients have benefited to date. We reviewed the dosing and regimens of patients who received adjuvant chemotherapy in the previous 5 years at our institution,and simulated the potential future of adjuvant chemotherapy in our institution.
Methods: Medical records of primary breast cancer patients were reviewed. We focused on the tri-weekly regimens, TC 4 cycles, and FEC 4 cycles - Docetaxel 4 cycles sequential regimen. We divided the patients into 3 groups; patients who received the standard dose without subsequent dose reduction or truncation (Group A), patients who started with the standard dose but experienced subsequent dose reduction (Group B), and patients who started out with a sub-standard dose (Group C).
Results: We have reviewed 51 cases - 76 arms of (neo-) adjuvant chemotherapy since April 2009. There were 26 case of TC chemotherapy and 25 case - 50 arms of FEC - Docetaxel sequential chemotherapy. Of the TC chemotherapy patients, 13 cases (50%) fell into group A, 5 (c.a. 10%) to group B, and 8 (c.a. 30%) to group C. Of the FEC arm of the FEC - Docetaxel regimen, 14 cases (28%) fell into group A, 2 (4%) to group B, and 34 (68%) in group C. Of the Docetaxel arm of the FEC - Docetaxel regimen, 30 cases (60%) fell into group A, 5 (10%) to group B, and 15 (30%) to group C.
Conclusions: Less than one third of patients have been receiving standard FEC chemotherapy in our institute, and pegfilgrastim may be indicated in all but selected patients. Also, potentially half of patients receiving TC chemotherapy, and one third of patients receiving docetaxel therapy could benefit. Furthermore, we have started using TCH (Docetaxel - Cyclophosphamide - Trastuzumab) for HER2 cases, a regimen that was difficult for Japanese patients before the use of pegfilgrastim.

キーワード

臓器別:乳腺

手法別:化学療法

前へ戻る